Research programme: protein therapeutics - Eli Lilly/Xencor

Drug Profile

Research programme: protein therapeutics - Eli Lilly/Xencor

Latest Information Update: 29 Apr 2008

Price : $50

At a glance

  • Originator Eli Lilly; Xencor
  • Class Proteins
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 29 Apr 2008 This collaboration is still active
  • 18 Apr 2005 Xencor has announced that Eli Lilly has exercised its option to develop a therapeutic protein created by Xencor
  • 27 Feb 2004 Preclinical trials in Undefined in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top